Sagimet Biosciences announced positive 52-week results from its Phase 3 OLE clinical trial of denifanstat for moderate to severe acne vulgaris, conducted by its license partner in China. The data showed sustained improvements in efficacy endpoints and good tolerability, reinforcing confidence as Sagimet prepares for its U.S. Phase 3 trial.
Sagimet Biosciences reported positive 52-week results from the Phase 3 OLE trial of denifanstat for acne, conducted by its partner Ascletis in China. This data is crucial as it demonstrates the long-term efficacy and safety of denifanstat, a key drug candidate for Sagimet, and directly supports the upcoming U.S. AURORA Phase 3 clinical trial. The positive results reduce clinical development risk and could lead to increased investor confidence in SGMT, potentially driving short-term stock appreciation. Long-term, successful U.S. trials and eventual approval would open up a significant market opportunity for Sagimet, as denifanstat could be the first oral treatment with a novel mechanism of action for acne in over forty years.